Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 18/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 17/20 | 0.49 |
| ▸ | CCND1 | P24385 | 10/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 9/20 | 0.46 |
| ▸ | CDK4 | P11802 | 7/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.46 |
| ▸ | CDK9 | P50750 | 6/20 | 0.46 |
| ▸ | CCND3 | P30281 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30804788 | 1.00 | CDK2 (0.49) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL30726224 | 0.92 | CDK2 (0.48) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL27033611 | 0.92 | CDK2 (0.48) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL27061975 | 0.91 | CDK2 (0.47) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL27061912 | 0.91 | CDK2 (0.47) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL27061905 | 0.91 | CDK2 (0.47) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL30804796 | 0.90 | CDK2 (0.48) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL27061972 | 0.90 | CDK2 (0.48) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL27061907 | 0.90 | CDK2 (0.47) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL27061909 | 0.90 | CDK2 (0.46) | CDK2CCNE1CCND1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092761-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092761-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | CCNI, CDK3, CDK1 | CDK2 5/4885CCNE1 53/4885CCND1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.